[HTML][HTML] Immune checkpoint inhibitor rechallenge in renal cell carcinoma: current evidence and future directions
E Sammarco, F Manfredi, A Nuzzo, M Ferrari, A Bonato… - Cancers, 2023 - mdpi.com
Simple Summary The advent of immune checkpoint inhibitors has dramatically changed the
history of advanced renal cell carcinoma treatment. Their use in first-line therapy provides an …
history of advanced renal cell carcinoma treatment. Their use in first-line therapy provides an …
[HTML][HTML] Metastatic Kidney Cancer: Does the Location of the Metastases Matter? Moving towards Personalized Therapy for Metastatic Renal Cell Carcinoma
The management of renal cell carcinoma (RCC) has been revolutionized over the past two
decades with several practice-changing treatments. Treatment for RCC often requires a …
decades with several practice-changing treatments. Treatment for RCC often requires a …
The role of CD200 in kidney cancer immune evasion
G Davies - 2023 - orca.cardiff.ac.uk
Kidney cancer is the 7th most common cancer type in the UK, with around 13,300 new cases
diagnosed every year, accounting for 4% of new cancer cases and 3% of all cancer deaths …
diagnosed every year, accounting for 4% of new cancer cases and 3% of all cancer deaths …
Efficacy and Safety of Durvalumab Rechallenge in Advanced Hepatocellular Carcinoma Patients Refractory to Prior Anti-PD-1 Therapy
KC Lai, YH Chen, YP Hung, NJ Chiang, MH Chen… - 2024 - researchsquare.com
Methods: From January 2016 to December 2023, 65 advanced HCC patients previously
treated with anti-PD-1 therapy were retrospectively enrolled and rechallenged with …
treated with anti-PD-1 therapy were retrospectively enrolled and rechallenged with …
[PDF][PDF] Rechallenge Immunotherapy in Former Interferon-Treated Patients with Metastatic Renal Cell Carcinoma
E Almuradova, C Engin, R Ismayilov - Eurasian Journal of Medical …, 2024 - ejmi.org
Objectives: The management of metastatic renal cell carcinoma (RCC) in the third-line
setting presents significant challenges due to limited data on treatment options beyond first …
setting presents significant challenges due to limited data on treatment options beyond first …